



Impact of early interferon- β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort

Sonsoles Salto-Alejandro^{a,b}, Zaira R. Palacios-Baena^{b,c,d,1}, José Ramón Arribas^{d,e,f}, Juan Berenguer^{f,g,h}, Jordi Carratalà^{d,i,j,k}, Inmaculada Jarrín^{d,1}, Pablo Ryan^{h,m,n}, Marta de Miguel-Montero^o, Jesús Rodríguez-Baño^{b,c,d,p,*}, Jerónimo Pachón^{a,b,p,*}, for the COVID-19@Spain Study Group

^a Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain

^b Institute of Biomedicine of Seville, Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, Seville, Spain

^c Unit of Infectious Diseases and Microbiology, University Hospital Virgen Macarena, Seville, Spain

^d CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain

^e Unit of Infectious Diseases, Service of Internal Medicine, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain

^f Instituto de Investigación Hospital Universitario La Paz, Madrid, Spain

^g Service of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

^h Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain

ⁱ Service of Infectious Diseases, Hospital Universitario de Bellvitge, Barcelona, Spain

^j Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain

^k Universitat de Barcelona, Barcelona, Spain

^l Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain

^m Service of Internal Medicine, Hospital Universitario Infanta Leonor, Madrid, Spain

ⁿ Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain

^o Fundación SEIMC/GeSIDA, Madrid, Spain

^p Department of Medicine, Universidad de Sevilla, Seville, Spain

ARTICLE INFO

Key words:

Interferon- β
Treatment
COVID-19
SARS-CoV-2
Mortality

ABSTRACT

Background: Interferon- β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon- β treatment in patients admitted with COVID-19 during the first wave of the pandemic. **Methods:** This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult patients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon- β , defined as early if started ≤ 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon- β therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis.

Results: Overall, 683 patients (17.9%) received early interferon- β therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon- β was 1.03 (95% CI, 0.82–1.30) in the overall cohort, 0.96 (0.82–1.13) in the PS-matched subcohort, and 0.89 (0.60–1.32) when interferon- β treatment was analyzed as a time-dependent variable.

* Corresponding authors at: Institute of Biomedicine of Seville, Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, Seville, Spain.

E-mail addresses: jesusrb@us.es (J. Rodríguez-Baño), pachon@us.es (J. Pachón).

¹ Join first author.

² Join last author.

<https://doi.org/10.1016/j.bioph.2021.112572>

Available online 22 December 2021

0753-3322/© 2021 The Author(s).

Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon- β therapy after hospital admission did not show an association with lower mortality. Whether interferon- β might be useful in the earlier stages of the disease or specific subgroups of patients requires further research.

1. Introduction

Since the pandemic of coronavirus disease 2019 (COVID-19) beginning in December 2019, caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, more than 272 million cases and 5.3 million deaths have been reported around the world as of 16 December 2021 [1]. Compared to the other beta coronaviruses that have caused epidemics over the last two decades, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 exhibits higher infectivity and lower fatality; hence, its destructive and expansive nature has led to the most devastating pandemic of the century [2].

Symptomatic SARS-CoV-2 infection presents a characteristic sequence of phases, beginning with accelerated viral replication that can escape the immune system, manifesting as an influenza-like illness. Within 7–10 days from symptom onset, an inflammatory phase develops in up to 20% of infected individuals, typically heralded by an organizing pneumonia [3]. Around 5% of patients subsequently deteriorate, with immune system dysregulation and stimulation of a hyperinflammatory state leading to acute respiratory distress syndrome (ARDS), endothelial damage and microvascular injury, and hypercoagulability [4].

In the absence of an antiviral drug with proven clinical efficacy against SARS-CoV-2, physicians across the world began treating patients with agents such as hydroxychloroquine, azithromycin, lopinavir/ritonavir, ivermectin, and remdesivir based on their empirically observed in vitro activity against coronaviruses. Most of these drugs are not used today because they did not demonstrate clinical efficacy in clinical trials, and there is currently no antiviral agent that can unequivocally reduce mortality. In this context, knowing the role of the inflammatory response in the development of severe complications, it is likely that developing a compound with both antiviral and immunomodulatory effects would be the most powerful approach to combat COVID-19.

Interferons (IFNs) are a group of cytokines that are crucial not only for antiviral immunity but also to dampen the innate response, preventing damage from pathogen-induced inflammation. However, coronaviruses encode interferon antagonists that actively interfere with host interferon induction and/or signaling [5]. There is evidence that the severity of COVID-19 is correlated with highly impaired type I IFN activity, characterized by no IFN- β and low IFN- α production [6]. Furthermore, it has been reported that at least 10% of patients with life-threatening pneumonia have neutralizing auto-antibodies (auto-Abs) against type I IFNs, which, like the abovementioned inborn errors, are associated with persistent blood viral load and an exacerbated inflammatory response [7]. The most important barriers to the use of type I IFNs as therapy are the lack of knowledge about timing and appropriate dosing and the increased chance of immunopathology by further stimulation of proinflammatory signals [8,9]. Promising results obtained from three randomized controlled trials with small sample sizes showed that subcutaneous injection of IFN- β in patients with moderate-to-severe COVID-19 improved clinical outcomes with no specific side effects [10–12]. However, two other multicenter randomized controlled trials, mostly in adult inpatients with mild-to-moderate COVID-19, did not show clinical efficacy of interferon treatment [13, 14].

With these data, we hypothesized that early administration of IFN- β would be associated with lower mortality compared to standard treatment alone. Therefore, we conducted a post hoc study using data from the multicenter retrospective COVID-19@Spain cohort to assess the protective effect of early IFN- β treatment compared with no IFN- β administration in patients hospitalized with COVID-19 [15].

2. Methods

2.1. Study design, sites, and participants

This post hoc analysis of the multicenter retrospective COVID-19@Spain cohort included 4035 consecutive adult patients with COVID-19 confirmed by real-time polymerase chain reaction (RT-PCR) assay, hospitalized in 127 Spanish centers between 1 January and 17 March 2020 and followed for 30 days after admission. The methodology has previously been described in detail [15–18]. In summary, all data were collected using an electronic case report form (eCRF) and added to a database built with Research Electronic Data Capture (REDCap) tools hosted at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)/AIDS Study Group (GESIDA) Foundation [19]. The Ethics Committee for Research with Medicines of Hospital General Universitario Gregorio Marañón approved the study and waived informed consent for the collection of clinical data. Approval was also obtained at each participating center, conforming with local requirements. Hospitals in which IFN- β was not used in any patient were excluded because they would cause a cluster effect not amenable to the control. Patients who died less than 48 h after admission were excluded from the study, whether they received IFN- β or not. This analysis was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations (Table S1) [20].

2.2. Variables and definitions

The outcome variable was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of IFN- β , which was classified as early IFN- β treatment (EIT) if started within ≤ 3 days (day of hospital admission was considered day 0), late IFN- β treatment (LIT) if started from day 4 onward, or no IFN- β treatment (NIT) if only standard treatment (not including IFN- β) was provided.

Additional exposure variables recorded at hospital admission were demographic data, chronic underlying conditions, admission symptoms and signs, laboratory findings, and severity according to the COVID-19 SEIMC score (14) and the WHO Clinical Progression Scale [21]. Additionally, other treatments for COVID-19 and use of respiratory support during hospitalization were recorded (Table 1).

2.3. Statistical analysis

The χ^2 or Fisher's exact test was used to compare categorical variables. When appropriate, continuous variables were dichotomized using data classification analysis, according to their association with mortality. Hospitals were classified into those with lower ($<30\%$) and higher ($\geq 30\%$) mortality as well as lower ($<40\%$) and higher ($\geq 40\%$) IFN- β prescription based on the 75th percentile cut-off point, and these variables were retained in the models. Cox regression was used to analyze the impact of EIT on 30-day mortality. Variables with $p < 0.10$ in univariate comparisons and those considered of clinical importance were entered into the multivariate models. The variables in the models were selected manually using a backward stepwise process. Interactions and collinearity were evaluated. Sensitivity analyses for 30-day mortality were performed, including changes in covariables and specific categorizations, using the variable IFN- β treatment as a time-dependent variable considered from the admission date. In addition, a propensity score (PS) for receiving EIT instead of NIT was calculated, and its ability to predict the observed data was assessed using the area under the receiver operating characteristic curve (AUROC) with a 95% confidence interval

Table 1
Features of Patients with COVID-19 According to Interferon Group.

Variable	EIT (n = 683)	LIT (n = 440)	NIT (n = 2685)	P Value (Early vs NIT)	P Value (Late vs NIT)
Male sex	451 (67)	297 (68.1)	1559 (58.8)	< .001	< .001
Age > 75 years	193 (28.3)	140 (31.9)	968 (36.1)	< .001	.09
Comorbidities					
Hypertension	337 (49.8)	240 (54.9)	1337 (50.1)	.90	.06
Diabetes	150 (22)	103 (23.7)	553 (20.8)	.49	.16
Obesity (BMI >30)	101 (16.3)	73 (18.3)	283 (11.9)	.003	< .001
Chronic heart disease	138 (20.3)	100 (23.3)	632 (23.8)	.05	.81
Chronic pulmonary disease (not asthma)	132 (19.4)	92 (21.3)	456 (17.1)	.16	.04
Asthma	52 (7.6)	33 (7.7)	197 (7.4)	.83	.85
Liver cirrhosis	5 (.7)	10 (2.3)	33 (1.2)	.17	.08
Chronic kidney disease stage 4 (eGFR <30 mL/min/1.73 m ²)	24 (3.5)	17 (3.9)	149 (5.6)	.03	.15
Chronic neurologic disorder	36 (5.3)	24 (5.6)	278 (10.4)	< .001	.002
Solid/hematologic neoplasm (active)	28 (4.1)	38 (8.8)	267 (10)	< .001	.42
Admission symptoms and signs					
Headache	65 (10)	47 (11.3)	292 (11.6)	.23	.85
Myalgia/arthralgia	178 (27.2)	119 (29)	611 (24.1)	.10	.03
Cough	547 (81)	320 (74.1)	1850 (69.7)	< .001	.07
Dyspnea	411 (60.8)	213 (49.1)	1191 (45)	< .001	.12
Vomiting/nausea	76 (11.4)	54 (12.7)	329 (12.6)	.43	.92
Diarrhea	92 (13.8)	62 (14.6)	290 (11.1)	.05	.04
Low SpO ₂ (age-adjusted) ^a	261 (43.8)	101 (26.6)	498 (20.9)	< .001	.01
Heart rate ≥ 100 bpm	175 (27)	90 (21.5)	565 (22)	.007	.83
SBP < 90 or DBP ≤ 60 mmHg	122 (19.1)	73 (17.8)	468 (18.3)	.64	.84
Temperature ≥ 38.5 °C	82 (12.5)	70 (16.5)	257 (9.9)	.06	< .001
More than 7 days from symptoms onset to admission	142 (20.8)	66 (15.0)	415 (15.5)	.001	.81
Admission laboratory findings					
Neutrophil count > 7500/μL	122 (17.9)	51 (11.6)	388 (14.8)	.047	.08
Lymphocyte count < 1000/μL	406 (59.9)	254 (58.1)	1357 (51.7)	< .001	.01
Platelets < 150,000/μL	239 (35.3)	163 (37.4)	783 (29.9)	.007	.002
D-dimer levels > 500 ng/mL	192 (62.7)	95 (55.9)	557 (56.2)	.04	.94
Lactate dehydrogenase > 250 U/L	369 (83.1)	197 (68.2)	1008 (58.8)	< .001	.003
C-reactive protein > 100 mg/L	295 (46.3)	112 (26.7)	603 (25.1)	< .001	.47
Treatment during hospitalization					
Remdesivir	30 (4.5)	10 (2.3)	8 (.3)	< .001	< .001
Lopinavir/ritonavir	635 (93.1)	413 (94.1)	1660 (62.4)	< .001	< .001
Tocilizumab	150 (22.4)	97 (22.5)	117 (4.5)	< .001	< .001
Corticosteroids	260 (38.4)	175 (40.1)	615 (23.3)	< .001	< .001
NIV or high flow (score of 6) ^b	178 (26.4)	116 (26.9)	214 (8.1)	< .001	< .001
Intubation and mechanical ventilation (score of 7) ^b	283 (41.4)	142 (32.3)	169 (6.3)	< .001	< .001
Vasopressors (score of 8) ^b	226 (33.4)	114 (26.5)	118 (4.5)	< .001	< .001
Dialysis or ECMO (score of 9) ^b	62 (9.2)	33 (7.6)	42 (1.7)	< .001	< .001
Outcome					
Alive currently hospitalized	110 (16.1)	56 (12.7)	132 (4.9)	< .001	< .001
Discharged alive	346 (50.7)	215 (48.9)	1930 (71.9)	< .001	< .001
Mortality at day 30	227 (33.2)	169 (38.4)	623 (23.2)	< .001	< .001
Center with high mortality	239 (35)	196 (44.5)	1042 (38.8)	.07	.02
Center with high interferon-β prescription	420 (61.5)	168 (38.2)	522 (19.4)	< .001	< .001
COVID-19 SEIMC Score (Median [IQR]) ^c	8 (5–13)	8 (5–13)	8 (4–16)	.89	.92
COVID-19 SEIMC Score Risk category ^c					
Low (0–2 points)	34 (5.9)	22 (5.9)	307 (13.8)	< .001	< .001
Moderate (3–5 points)	122 (21.3)	75 (20.3)	473 (21.2)	.99	.89
High (6–8 points)	140 (24.4)	92 (24.9)	410 (18.4)	.046	.04
Very high (9–30 points)	277 (48.3)	181 (48.9)	1040 (46.6)	.72	.65
Days from hospital admission to intubation (Median [IQR])	2 (1–4)	5 (3–7)	4 (1–7)	.01	.05

Data are presented as No. (%). P values are calculated by χ^2 , Fisher's test or Mann-Whitney's *U* test.

Abbreviations: EIT, early interferon-β treatment; LIT, late interferon-β treatment; NIT, no interferon-β treatment; BMI, body mass index; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus infection; AIDS, acquired immunodeficiency syndrome; SpO₂, peripheral capillary oxygen saturation; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIV, non-invasive ventilation; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range.

^aAge-adjusted low SpO₂ ≤ 90% for patients aged > 50 years and ≤ 93% for patients aged ≤ 50 years.

^bSeverity rating according to the WHO Clinical Progression Scale, ranged from 0 (not infected) to 10 (dead).

^cSimple scoring system to predict 30-day mortality on presentation in hospitalized patients with COVID-19 based on age (years), low SpO₂ (age-adjusted), neutrophil-to-lymphocyte ratio, estimated glomerular filtration rate (CKD-EPI), dyspnea and sex (14).

(CI). The PS was used in two ways: as a covariate to control for residual confounders in multivariate models and to perform a matched cohort analysis in which patients undergoing EIT and NIT were paired (1:1) according to their PS using calipers with 0.01 standard deviation. Mortality in the matched pairs was compared by Cox regression. Regarding missing data, Little's MCAR test was used to verify a random pattern, and imputation was performed using the Markov chain Monte Carlo method. All statistical analyses were carried out using SPSS software (SPSS 26.0, IBM Corp., Armonk, NY, USA).

3. Results

In all, 4035 patients with COVID-19 included in the COVID-19@Spain cohort were eligible for analysis; 130 patients were excluded for being treated at one of 19 centers where IFN-β was not used, and 97 because they died ≤ 48 h after hospital admission. Finally, 3808 patients were included in this study: 683 (17.9%) received early IFN-β treatment (median (IQR) days from admission, 1 (1–2)), 440 (11.6%) received late IFN-β treatment (median (IQR) days from

admission, 5 (4–8)), and 2685 (70.5%) received no IFN- β treatment. The study flowchart is presented in Fig. 1.

The patient characteristics are shown in Table 1. Compared to patients who underwent EIT, those in the NIT group were more frequently over 75 years old; had chronic heart, kidney, and neurological diseases; and suffered from active solid or hematologic neoplasms. Notwithstanding, they presented a significantly lower proportion of severe symptoms and signs (i.e., dyspnea, peripheral oxygen desaturation, and tachycardia), in conjunction with fewer laboratory indicators of high risk (i.e., neutrophilia, lymphopenia, thrombocytopenia, and elevated levels of D-dimer, lactate dehydrogenase, and C-reactive protein), which is consistent with a diminished prevalence of the inflammatory phase of COVID-19 on admission (142 patients in EIT and 415 in NIT; $p = 0.001$). Thus, patients in the NIT group less often reached higher disease severity scores (from 6 to 9, according to the WHO Clinical Progression Scale; from 6 to 8, according to the COVID-19 SEIMC score) [18,21] and did not receive as broad therapy (including remdesivir, tocilizumab, and corticosteroids) as patients in the EIT group.

3.1. Variables associated with EIT

The association of different variables with EIT is shown in Table 2. Patients receiving EIT more frequently had severe signs and symptoms and high values of inflammatory biomarkers, and received treatment with tocilizumab, corticosteroids, and respiratory and hemodynamic support in higher proportions.

3.2. Mortality analysis

The mortality rates were 33.2% (227/683), 38.4% (169/440), and 23.2% (623/2685) in patients with EIT, LIT, and NIT, respectively ($p < 0.001$ for EIT vs. NIT) (Table 1). Univariate and multivariate analyses of variables associated with 30-day mortality are shown in Table 3. The multivariate analysis selected the following factors as being associated with mortality: age > 75 years (HR, 2.37; 95% CI, 2.00–2.81; $p < 0.001$), dyspnea (HR, 1.49; 95% CI, 1.24–1.78; $p < 0.001$), low peripheral capillary oxygen saturation (SpO₂) (HR, 1.55; 95% CI, 1.26–1.90; $p < 0.001$), lymphocyte count $< 1000/\mu\text{L}$ (HR, 1.28; 95% CI, 1.08–1.53; $p = 0.01$), platelets $< 150,000/\mu\text{L}$ (HR, 1.29; 95% CI,

1.08–1.53; $p = 0.004$), lactate dehydrogenase > 250 U/L (HR, 1.44; 95% CI, 1.19–1.76; $p < 0.001$), C-reactive protein > 100 mg/L (HR, 1.42; 95% CI, 1.19–1.69; $p < 0.001$), and corticosteroids (HR, 1.32; 95% CI, 1.11–1.56; $p = 0.002$). Early IFN- β treatment did not show an association with mortality. The model exhibited good predictive ability (AUROC, 0.86 (95% CI, 0.84–0.91; $p = 0.004$)). No important interactions were identified.

We then investigated the impact of EIT vs. NIT, including the PS for EIT (LIT patients were excluded from this analysis) (Table 3). No significant collinearity was found between PS and other variables. Similarly, no difference was observed among the patients undergoing EIT (adjusted hazard ratio (HR), 1.03 (95% CI, 0.82–1.30; $p = 0.78$)); AUROC for this model: 0.81 (95% CI, 0.77–0.83; $p < 0.001$).

The estimations of the associations of EIT with mortality in the sensitivity analyses were consistent with the analysis of the whole cohort. When including the COVID-19 SEIMC score as a continuous variable instead of the component variables (age, dyspnea, low SpO₂, and lymphocyte count), the adjusted hazard ratio for EIT was 1.08 (95% CI, 0.93–1.25; $p = 0.32$) (Table S2). When excluding the covariates lopinavir/ritonavir, tocilizumab, and corticoids, the adjusted hazard ratio for EIT was 1.10 (95% CI, 0.96–1.27; $p = 0.16$) (Table S3). Therefore, these treatments were not confounding factors for the association between EIT and mortality. We also studied interferon treatment as a time-dependent covariate within the entire cohort, having an adjusted hazard ratio of 0.89 (95% CI, 0.59–1.32; $p = 0.55$) (Table S4).

Finally, we matched 144 pairs of patients receiving EIT or NIT based on PS. Matched subcohorts had similar exposure frequency to all variables (Table 4). Early IFN- β treatment did not show an association with mortality in this analysis (HR, 0.96 (95% CI, 0.82–1.13; $p = 0.99$)).

4. Discussion

In this post hoc analysis of a multicenter cohort from the first wave of the COVID-19 pandemic, we analyzed the association of early IFN- β administration with mortality. Patients receiving EIT more frequently had severe symptoms and signs in addition to high values of inflammatory biomarkers, and a higher proportion required respiratory and/or hemodynamic support than those receiving LIT or NIT. The crude mortality rates were 33.2%, 38.4%, and 23.2% in patients with EIT, LIT,




Fig. 1. Study flowchart showing the initial patients from the COVID-19@Spain cohort and the reasons for exclusion, for being treated at centers where IFN- β was not used and because they died ≤ 48 h after hospital admission. Finally, 3808 patients were included for analysis of the impact of early interferon- β treatment.

Table 2
Analysis of the Association of Different Variables with Early Interferon- β Treatment.

Variable	EIT (n = 683)	LIT or NIT (n = 3125)	Crude OR (95% CI)	P Value
Male sex	451 (67)	1856 (60.1)	1.34 (1.25–1.44)	< .001
Age > 75 years	193 (28.3)	1108 (35.5)	.72 (.67–.77)	< .001
Obesity (BMI >30)	101 (16.3)	356 (12.8)	1.31 (1.19–1.43)	< .001
Chronic heart disease	138 (20.3)	732 (23.7)	.81 (.75–.89)	< .001
Dyspnea	411 (60.8)	1404 (45.6)	1.84 (1.72–1.98)	< .001
Low SpO ₂ (age-adjusted) ^a	261 (43.8)	599 (21.7)	2.69 (2.51–2.89)	< .001
Heart rate $\geq$ 100 bpm	175 (27)	655 (21.9)	1.31 (1.21–1.42)	< .001
More than 7 days from symptoms onset to admission	142 (20.8)	481 (15.4)	1.44 (1.33–1.57)	< .001
Neutrophil count > 7500/ μ L	122 (17.9)	439 (14.4)	1.30 (1.19–1.42)	< .001
Lymphocyte count < 1000/ μ L	406 (59.9)	1611 (52.6)	1.34 (1.26–1.44)	< .001
Platelets < 150,000/ μ L	239 (35.3)	946 (30.9)	1.22 (1.13–1.31)	< .001
D-dimer levels > 500 ng/mL	192 (62.7)	652 (56.2)	1.32 (1.18–1.46)	< .001
Lactate dehydrogenase > 250 U/L	369 (83.1)	1205 (60.2)	3.26 (2.93–3.63)	< .001
C-reactive protein > 100 mg/L	295 (46.3)	715 (25.3)	2.55 (2.37–2.74)	< .001
Lopinavir/ritonavir	635 (93.1)	2073 (66.9)	6.70 (5.91–7.59)	< .001
Tocilizumab	150 (22.4)	214 (7)	3.83 (3.49–4.20)	< .001
Corticosteroids	260 (38.4)	790 (25.7)	1.80 (1.68–1.94)	< .001
NIV or high flow (score of 6) ^b	178 (26.4)	330 (10.7)	2.96 (2.73–3.22)	< .001
Intubation and mechanical ventilation (score of 7) ^b	283 (41.4)	311 (10)	5.94 (5.51–6.41)	< .001
Vasopressors (score of 8) ^b	226 (33.4)	232 (7.6)	6.00 (5.52–6.53)	< .001
Center with high interferon- β prescription ^c	420 (61.5)	690 (22.1)	5.64 (5.25–6.06)	< .001

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: EIT, early interferon- β treatment; LIT, late interferon- β treatment; NIT, no interferon- β treatment; OR, odds ratio; CI, confidence interval; BMI, body mass index; SpO₂, peripheral capillary oxygen saturation; NIV, non-invasive ventilation.

^aAge-adjusted low SpO₂ $\leq$ 90% for patients aged > 50 years and $\leq$ 93% for patients aged $\leq$ 50 years.

^bSeverity rating according to the WHO Clinical Progression Scale, ranged from 0 (not infected) to 10 (dead).

^cThe centers were dichotomized into low (<40%) and high ($\geq$ 40%) proportion of IFN- β prescription.

and NIT, respectively. The factors independently associated with 30-day mortality were age > 75 years, dyspnea, low peripheral capillary oxygen saturation, lymphopenia, thrombocytopenia, high values of lactate dehydrogenase and C-reactive protein, and the use of corticosteroids. Early IFN- β treatment did not show an association with mortality. Moreover, the analysis of 144 pairs of patients receiving EIT or NIT based on PS did not reveal an association of EIT with lower mortality.

To the best of our knowledge, this is the biggest study providing information on the effectiveness of systemic early IFN- β administration vs. standard treatment alone in patients with moderate-to-severe COVID-19 addressing the confounding effects of other potential targeted drugs. Our hypothesis, that early administration of IFN- β would be associated with lower mortality compared to standard treatment alone, is shared by the currently ongoing INTERCOP study, an open-label monocentric phase II randomized controlled trial (ClinicalTrials.gov identifier: NCT04449380) [22].

The unprecedented emergency of the COVID-19 pandemic, with no available medications of fully proven efficacy, provided a compelling reason to repurpose drugs already marketed for other indications. Among these, the use of IFN- β seemed immediately feasible for a number of reasons: (i) direct in vitro antiviral activity against SARS-CoV-2 [23]; (ii) previous encouraging experience in mice and nonhuman primate models of MERS [24,25]; (iii) promising results in reducing mortality when combined with lopinavir–ritonavir and started within seven days after symptom onset [26]; and (iv) safety in patients with ARDS, in addition to long-term consolidated evidence of tolerability as an established treatment for multiple sclerosis [27,28].

The very promising results from a Chinese multicenter randomized trial with 127 patients enrolled suggest that subcutaneous INF- β is a key component for success in shortening the viral shedding of a combined therapy that also includes lopinavir–ritonavir and ribavirin [10]. However, the analysis was confounded by the exclusion of a 34-patient subgroup (admitted $\geq$ 7 days after symptom onset), for whom INF- β was omitted due to concerns about proinflammatory side effects. Furthermore, critically ill patients were not eligible for the study, impeding the application of the findings to severe cases. Another single-center randomized controlled trial in Iran recruited 60 severely ill patients to evaluate the efficacy of subcutaneous INF- β . In short, the

intervention group had a shorter time to clinical improvement, and their mortality rate was almost half that of the control group, although the difference was not statistically significant [11]. Including moderate patients and earlier administration of exogenous INF- β (mean time from enrollment to first dose was 5.4 days) might have yielded more substantial results and minimized the adverse effects (essentially abnormalities in liver injury biomarkers). A third single-center randomized controlled trial showed a significant decrease in mortality in patients receiving early therapy (less than 7–10 days from the onset of symptoms) with subcutaneous INF- β , but not late administration of INF- β [12].

The WHO Solidarity Trial [13], a multicenter randomized controlled trial, did not show lower mortality in the interferon group vs. control (11.8% vs. 10.5%, $p = 0.11$). Both groups were similar, but contrary to our study, only 6.7% (INF- β) and 6.3% (control) of patients were on ventilation support, and only 33.7% and 34.7% were hospitalized $\geq$ 2 days. Similarly, a multicenter randomized controlled trial by Kalil et al. did not show efficacy of INF- β combined with remdesivir compared to remdesivir alone concerning time to recovery [14]. Patients had mostly mild-to-moderate COVID-19, with only 7% in both groups requiring non-invasive ventilation or high-flow oxygen therapy.

Finally, Monk et al. assessed the efficacy and safety of inhaled INF- β vs. placebo for the treatment of patients admitted with non-severe COVID-19 (only 2 out of 98 patients requiring non-invasive ventilation or high-flow oxygen), showing a significant improvement in the clinical condition, on the basis of the WHO Ordinal Scale for Clinical Improvement, during the dosing period in the intention-to-treat population [29].

With this as background, we conducted a post hoc propensity score-adjusted study of 3808 consecutive patients with moderate-to-severe COVID-19, investigating the effectiveness of subcutaneous INF- β treatment. In this observational study, we mimicked the assignment of patients to treatment arms and the intention-to-treat analysis inherent in any randomized trial. Therefore, before performing any analysis, we defined EIT as IFN- β started $\leq$ 3 days from admission and excluded patients for whom the endpoint was reached in this period or those who started treatment from day 4 onward in order to avoid immortal time bias. We used a single robust primary outcome, mortality, because some

Table 3

Univariate and Multivariate Analyses of Risk Factors Associated with All-cause 30-Day Mortality Using Cox Regression.

Variable	Deceased (n = 1019)	Alive (n = 2789)	Crude Analysis		Adjusted Analysis ^a		EIT vs NIT, Adjusted by PS ^b	
			HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Male sex	700 (69.5)	1607 (58.4)	1.31 (1.15–1.50)	< .001	...	...	...	...
Age > 75 years	621 (61)	680 (24.4)	2.66 (2.34–3.01)	< .001	2.37 (2.00–2.81)	< .001	2.51 (2.06–3.05)	< .001
Obesity (BMI > 30)	163 (18.3)	294 (11.7)	1.29 (1.09–1.52)	.004	...	...	...	...
Chronic heart disease	399 (39.6)	471 (17.1)	1.87 (1.65–2.13)	< .001	...	...	...	...
Dyspnea	613 (61.2)	1202 (43.7)	1.74 (1.54–1.98)	< .001	1.49 (1.24–1.78)	< .001	1.39 (1.12–1.71)	.003
Low SpO ₂ (age-adjusted) ^c	366 (42.9)	494 (19.8)	2.05 (1.75–2.41)	< .001	1.55 (1.26–1.90)	< .001	1.67 (1.30–2.14)	< .001
Heart rate ≥ 100 bpm	239 (24.5)	591 (22.4)	1.15 (.99–1.33)	.06	...	...	...	...
More than 7 days from symptoms onset to admission	99 (9.7)	524 (18.8)	.67 (.54–.83)	< .001	...	...	...	...
Neutrophil count > 7500/μL	244 (24.3)	317 (11.6)	1.60 (1.38–1.84)	< .001	...	...	...	...
Lymphocyte count < 1000/μL	650 (64.9)	1367 (49.9)	1.55 (1.36–1.77)	< .001	1.28 (1.08–1.53)	.01	1.25 (1.03–1.51)	.03
Platelets < 150,000/μL	382 (37.9)	803 (29.4)	1.30 (1.14–1.48)	< .001	1.29 (1.08–1.53)	.004	1.28 (1.05–1.56)	.01
D-dimer levels > 500 ng/mL	233 (67.1)	611 (54.6)	1.27 (1.01–1.59)	.04	...	...	...	...
Lactate dehydrogenase > 250 U/L	458 (73.4)	1116 (61.2)	1.49 (1.25–1.78)	< .001	1.44 (1.19–1.76)	< .001	1.50 (1.20–1.88)	< .001
C-reactive protein > 100 mg/L	407 (44.1)	603 (23.7)	1.87 (1.65–2.14)	< .001	1.42 (1.19–1.69)	< .001	1.47 (1.21–1.79)	< .001
Lopinavir/ritonavir	743 (72.9)	1982 (71.1)	.93 (.81–1.07)	.29	.92 (.75–1.13)	.42	.88 (.64–1.20)	.41
Tocilizumab	122 (12.2)	242 (8.9)	.90 (.75–1.09)	.27	.80 (.63–1.03)	.08	.76 (.46–1.26)	.28
Corticosteroids	439 (43.6)	611 (22.3)	1.52 (1.34–1.72)	< .001	1.32 (1.11–1.56)	.002	1.33 (1.08–1.63)	.01
Interferon-β treatment								
No interferon-β treatment	623 (61.1)	2062 (73.9)	Reference	.01	Reference	.34	Reference	...
Early interferon-β treatment	227 (26.7)	456 (18.1)	1.28 (1.10–1.49)	.001	1.01 (.80–1.26)	.97	1.03 (.82–1.30)	.78
Late interferon-β treatment	169 (21.3)	271 (11.6)	1.08 (.91–1.28)	.37	1.19 (.95–1.49)	.14	Excluded	...
Center with high mortality	543 (53.3)	934 (33.5)	1.72 (1.52–1.95)	< .001	1.69 (1.43–2.00)	< .001	1.68 (1.39–2.03)	< .001
Propensity score ^d	...	...	...	...	...	...	.98 (.27–3.62)	.97

Data are presented as No. (%) unless otherwise indicated. Crude and adjusted HR have been calculated from imputed data.

Abbreviations: EIT, early interferon-β treatment; NIT, no interferon-β treatment; PS, propensity score; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SpO₂, peripheral capillary oxygen saturation.^aThe area under the receiver operating characteristic (AUROC) curve of the model was .86 (95% CI, .84–.91), *P* = .004.^bPatients in the late interferon-β treatment group were excluded from this analysis.^cAge-adjusted low SpO₂ ≤ 90% for patients aged > 50 years and ≤ 93% for patients aged ≤ 50 years.^dCalculated only for patients in the early interferon-β treatment and no interferon-β treatment groups. The variables included in the propensity score were sex, age, obesity, chronic heart disease, dyspnea, low SpO₂, hyperinflammation phase, neutrophil count, lymphocyte count, platelets, D-dimer, lactate dehydrogenase, C-reactive protein, lopinavir/ritonavir, tocilizumab, corticosteroids, and high-mortality hospital. The AUROC curve of the PS model was .83 (95% CI, .81–.87), *P* < .001.

patients may be candidates for additional medical treatment but not for intensive care, owing to previous conditions. Regarding confounders, we used propensity scores in different ways to control for indication bias. In the crude analysis, the EIT group showed higher mortality, as it was administered to patients with more severe disease. After adjustment for other well-known risk mortality predictors [15,30,31], EIT was not found to be associated with mortality.

Regarding IFN treatment, studies supporting its use in COVID-19 are still scarce and certainly do not address the phase of the disease in which to start administration. Data on the increased severity of COVID-19 in patients with no endogenous IFN-β and low IFN-α production [6] or with neutralizing auto-Abs against type I IFNs [7] suggest a potential role for early IFN treatment. In addition, a cohort analysis of patients with multiple sclerosis showed that IFN administration is preventive of severe COVID-19 [32]. Other issues also have to be considered, such as the dosage and PEGylation to prolong the antiviral effect, as per the methods used in other mammals for acute and chronic viral diseases [33, 34]. An important aspect in our study is the fact that a substantial

proportion of patients already had > 7 days of symptoms when admitted, and this was more frequent among those with EIT, meaning that the window of opportunity for benefiting from IFN-β treatment may have already passed when the drug was administered.

The present study has several limitations. First, controlling for confounders in any observational study can be incomplete despite all efforts. Second, a wide range of dosing regimens was used in all groups. Third, the investigators were not blinded to the exposure; however, we used a hard outcome and included consecutive cases. Fourth, our data were not specific to or complete for adverse events, and this is a crucial aspect that should be considered in more detail in future studies. Moreover, we had no access to the follow-up RT-PCR results; thus, we were unable to determine the time to a negative test or to shed further light on the effect of IFN-β on viral dynamics. Regarding the association found between the use of corticosteroids and mortality, the weaknesses are that the study was not designed to evaluate their efficacy, the late time of administration in many cases, and the probable different dosages depending on the clinical situation of the patients. Finally, the cohort

Table 4
Comparison of Matched Patients According to Propensity Score.

Variable	Overall Cohort (N = 3368) ^a			Propensity Score-Matched Cohort (N = 288) ^b		
	EIT (n = 683)	NIT (n = 2685)	P Value	EIT (n = 144)	NIT (n = 144)	P Value
Male sex	451 (67)	1559 (58.8)	< .001	97 (67.4)	98 (68.1)	.90
Age > 75 years	193 (28.3)	968 (36.1)	< .001	30 (20.8)	38 (26.4)	.27
Obesity (BMI >30)	101 (16.3)	283 (11.9)	.003	23 (16)	19 (13.2)	.50
Chronic heart disease	138 (20.3)	632 (23.8)	.05	23 (16)	24 (16.7)	.87
Dyspnea	411 (60.8)	1191 (45)	< .001	93 (64.6)	86 (59.7)	.40
Low SpO ₂ (age-adjusted) ^c	261 (43.8)	498 (20.9)	< .001	59 (41)	53 (36.8)	.47
Heart rate ≥ 100 bpm	175 (27)	565 (22)	.01	40 (27.8)	39 (27.1)	.90
> 7 days from onset to admission	142 (20.8)	415 (15.5)	.001	29 (20.1)	31 (21.5)	.77
Neutrophil count > 7500/μL	122 (17.9)	388 (14.8)	.047	21 (14.6)	23 (16)	.74
Lymphocyte count < 1000/μL	406 (59.9)	1357 (51.7)	< .001	91 (63.2)	83 (57.6)	.34
Platelets < 150,000/μL	239 (35.3)	783 (29.9)	.01	48 (33.3)	54 (37.5)	.46
D-dimer levels > 500 ng/mL	192 (62.7)	557 (56.2)	.04	96 (66.7)	91 (63.2)	.54
Lactate dehydrogenase > 250 U/L	369 (83.1)	1008 (58.8)	< .001	115 (79.9)	117 (81.3)	.77
C-reactive protein > 100 mg/L	295 (46.3)	603 (25.1)	< .001	66 (45.8)	68 (47.2)	.81
Lopinavir/ritonavir	635 (93.1)	1660 (62.4)	< .001	142 (98.6)	142 (98.6)	.99
Tocilizumab	150 (22.4)	117 (4.5)	< .001	32 (22.2)	36 (25.2)	.56
Corticosteroids	260 (38.4)	615 (23.3)	< .001	63 (43.8)	64 (44.4)	.91
Deceased	227 (33.2)	623 (23.2)	< .001	38 (26.4)	38 (26.4)	1.00
Center with high mortality	239 (35)	1042 (38.8)	.07	50 (34.7)	47 (32.6)	.71

Data are presented as No. (%). P values are calculated by Cox regression.

Abbreviations: EIT, early interferon-β treatment; NIT, no interferon-β treatment; BMI, body mass index; SpO₂, peripheral capillary oxygen saturation.

^aPatients in the late interferon-β treatment group were excluded from this analysis.

^bThe Propensity score was calculated only for patients in the early interferon-β treatment and no interferon-β treatment groups. The variables included in the propensity score were sex, age, obesity, chronic heart disease, dyspnea, low SpO₂, hyperinflammation phase, neutrophil count, lymphocyte count, platelets, D-dimer, lactate dehydrogenase, C-reactive protein, lopinavir/ritonavir, tocilizumab, corticosteroids, and high-mortality hospital. The AUROC curve of the PS model was.83 (95% CI,.81–.87), $P < .001$.

^cAge-adjusted low SpO₂ ≤ 90% for patients aged > 50 years and ≤ 93% for patients aged ≤ 50 years.

^dSeverity rating according to the WHO Clinical Progression Scale, ranged from 0 (not infected) to 10 (dead).

was built during the first wave of the pandemic in Spain; management may have changed afterward. The strengths include the multicenter nature of participation, adequate sample size, and the use of standardized scoring systems and a clear, solid endpoint together with advanced statistical analyses, including the imputation of missing data using the Markov chain Monte Carlo method.

In conclusion, our findings did not find an association between early IFN-β therapy after hospital admission and any mortality benefit in patients admitted because of COVID-19. Additional data are needed for IFN-β administration at even earlier stages of the disease and in association with other drugs such as tocilizumab or corticosteroids. Finally, whether the drug would be useful specifically in patients with low IFN production needs to be investigated.

Collaborators

The COVID-19@Spain Study Group members.

Fundación SEIMC-GESIDA: Aznar Muñoz Esther, Gil Divasson Pedro. **Hospital Universitario Virgen Macarena:** Retamar Pilar, Valiente Adoración, López-Cortés Luis E., Sojo-Dorado Jesús, Bravo-Ferrer José, Salamanca Elena, Pérez-Palacios Patricia, Gandullo-Moro María, Ruiz-Hueso Rocío, Moya-González Natalia, Peral Enrique, Valido-Morales Agustín, Pavón-Masa María. **Hospital Universitario La Paz:** Díaz Menéndez Marta, De la Calle Prieto Fernando, Arsuaga Vicente Marta, Ramos Ramos Juan Carlos, De Miguel Buckley Rosa, Cadiñanos Loidi Julen, Marcelo Calvo Cristina, Vasquez Manau Julia, Mora Rillo Marta, Loeches Yagüe Belén, Ramos Ruperto Luis, García-Rodríguez Julio, Montejano Sánchez Rocío, Díaz Pollan Beatriz. **Hospital Universitario Gregorio Marañón:** López Juan Carlos, Ramírez-Schacke Margarita, Gutiérrez Isabel, Tejerina Francisco, Aldámiz-Echevarría Teresa, Díez Cristina, Fanciulli Chiara, Pérez-Latorre Leire, Parras Francisco, Catalán Pilar, García-Leoni María E., Pérez-Tamayo Isabel, Puente Luis, Cedeño Jamil. **Hospital Infanta Leonor:** Such-Díaz Ana, Álvaro-Alonso Elena, Izquierdo-García Elsa, Torres-Macho Juan, Cuevas Guillermo, Notario Helena, Mestre-Gómez Beatriz, Jiménez-

González de Buitrago Eva, Fernández-Jiménez Inés, Tebar-Martínez Ana Josefa, Brañas Fátima, Valencia Jorge, Pérez-Butragueño Mario, Muñoz-Rivas Nuria. **Hospital Universitario de Bellvitge:** Abelenda-Alonso Gabriela, Ardanuy Carmen, Bergas Alba, Cuervo Guillermo, Domínguez María Ángeles, Fernández-Huerta Miguel, Gudíol Carlota, Lorenzo-Esteller Laia, Niubó Jordi, Pérez-Recio Sandra, Podzamczar Daniel, Pujol Miquel, Rombauts Alexander, Trullen Núria. **Hospital Universitario Virgen del Rocío:** Molina José, Álvarez-Marín Rocío, García-Gutiérrez Manuel, Paniagua María, Alarcón Arístides, Gil-Navarro María Victoria, Giménez Luis, Camacho-Martínez Pedro, Merino Laura, Caballero-Eraso Candela, Paradas Carmen, Valencia-Martín José, Fernández-Delgado Esperanza. **Complejo Hospitalario Virgen de la Salud:** Sepúlveda Berrocal M^a Antonia, Yera Bergua Carmen, Tolezano Sierra Pilar, Cano Llorente Verónica, Zafar Iqbal-Mirza Sadaf, Muñiz Gema, Martín Pérez Inmaculada, Mozas Morínigo Helena, Alguacil Ana, García Butenegro María Paz. **Hospital Universitario Rafael Méndez:** Peláez Ballesta Ana Isabel, Morcillo Rodríguez Elena. **Hospital Universitario de Cruces:** Goikoetxea Agirre Josune, Bereciartua Bastarrica Elena, Guio Carrion Laura, Euba Ugarte Gorane. **Hospital de Melilla:** Pérez Hernández Isabel A., Román Soto Sergio. **Hospital San Eloy de Barakaldo:** Silvarriño Fernández Rafael, Ugalde Espiñeira Jon. **Hospital Universitario Central de Asturias:** Asensi Víctor, Rivas-Carmenado María, Suárez Pérez Lucía, Suárez Díaz Silvia. **Hospital General Universitario de Alicante:** Boix Vicente, Díez Martínez Marcos, Carreres Candela Melissa. **Hospital Virgen de la Victoria:** Gómez-Ayerbe Cristina, Sánchez-Lora Javier, Velasco Garrido José Luis, López-Jodar María, Santos González Jesús. **Hospital Universitario Puerto Real:** Ruiz Aragón Jesús, Virto Peña Ianire. **EOXI Pontevedra e Salnés:** Alende Castro Vanessa, Fernandez Morales Marta. **Hospital de Figueres:** Vega Molpeceres Sonia, Pons Viñas Estel. **Hospital Sant Jaume de Calella:** del Río Pérez Oscar, Valero Rovira Silvia. **Hospital del Mar:** Gómez-Junyent Joan, Castañeda Espinosa Silvia, Cánepa María Cecilia, Villar-García Judit, Gimenez Argente Carmen, Soldado Folgado Jade, Nogués Solán Xavier, de Pablo Miró Mar, Cazador Labat Miriam. **Hospital Clínico Universitario Virgen de**

la Arrixaca-IMIB: García Vázquez Elisa, Marín Real Sonia, Roura Piloto Aychel Elena. **Hospital de Can Misses:** García Almodóvar Esther. **Hospital de Sagunto:** Sáez Barberá Carmen, Karroud Zineb. **Hospital Clínico San Cecilio:** Vinuesa García David, Hernández Quero José, Faro-Míguez Naya, Benavente-Fernandez Alberto. **Hospital Universitario Príncipe de Asturias:** Novella Mena María, Hernández Gutiérrez Cristina, Sanz Moreno José, Pérez Tanoira Ramón, Barbero Allende José María, Culebras López Ana María, García Sánchez Marta, Arranz Caso Alberto, Cuadros González Juan, Álvarez de Mon Soto Melchor. **Parc Sanitari Sant Joan de Déu:** Díaz-Brito Fernández Vicens, Sanmarti Vilamala Montserrat, Gabarrell Pascuet Aina, Esteve-Palau Erika, España Cueto Sergio, Álvarez Moya Maria Carmen, Medina Salas Francisco, García Aranda Geneva. **Hospital Nuestra Señora de Gracia:** Sáez Escolano Paula, Solsona Fernández Sofía. **HC Marbella Internacional Hospital:** Sempere Alcocer Marco Antonio, Martin Nicole. **Hospital Universitario La Princesa:** De los Santos Gil Ignacio, García-Fraile Lucio, Sampedro Núñez Miguel, Barrios Blandino Ana, Rodríguez Franco Carlos, Useros Brañas Daniel, Villa Martí Almudena, Oliver Ortega Javier, Costanza Espiño Álvarez Alexia, Sanz Sanz Jesús. **Hospital Josep Trueta:** Rexach Fumaña María, Policarpo Torres Guillem, Ortega Montoliu Meritxell. **Hospital Dos de Maig-Consorcio Sanitari Integral:** Sala Jofre Clara, Casas Rodríguez Susana. **Hospital Arnau de Vilanova-Llíria:** Tortajada Alamilla Cecilia, Oltra Carmina. **Hospital General Universitario de Elche:** Masía Canuto Mar, Gutiérrez Roderio Félix. **Hospital Clínico Universitario de Valencia:** Oltra Sempere M^a Rosa, Vela Berna Sara. **Complejo Asistencial de Ávila:** Pedromingo Kus Miguel, Garcinuño María Ángeles, Fiorante Silvana, Pérez Pinto Sergio. **Hospital Comarcal de Alcañiz:** Hernández Machín Pilar, Alastrué Violeta Alba. **Hospital Universitario Marqués de Valdecilla:** Fariñas Álvarez María Carmen, González Rico Claudia, Arnaiz de las Revillas Francisco, Calvo Jorge, Gozalo Mónica. **Hospital Quirón-Salud de Torrevieja:** Mora Gómez Francisco. **Hospital Universitario Miguel Servet:** Latorre-Millán Miriam, Milagro Beamonte Ana, Rezusta López Antonio, Roc Lourdes. **Hospital de Barcelona SCIAS:** Meije Yolanda, Ribera Puig Alba, Duarte-Borjes Alejandra, Sanz Salvador Xavier. **Fundación Hospital Universitario Alcorcón:** Lora García Juan Emilio, Martín-Segarra Oriol. **Hospital Álvaro Cunqueiro:** Pérez-Rodríguez M. Teresa, Pérez González Alexandre. **Complejo Asistencial Universitario de Salamanca:** Belhassen-García Moncef, Tejera Pérez Rosa, López-Bernus Amparo, Carbonell Cristina. **Hospital Universitario Severo Ochoa:** Cantón De Seoane Juan, Torres Perea Rafael, Cervero Jiménez Miguel, Avilés Parra Juan Pablo, Cayuela Rodríguez Lucía, Kamel Rey Sara Lidia, Roa Alonso David, Martín Rojo Lidia, García Escudero Laura, Orejas Gallego Alberto. **Hospital CIMA-Sanitas:** Pelegrín Iván, Rouco Esteves Marques Rosana. **Hospital HLA Inmaculada:** Parra Ruiz Jorge, Ramos Sesma Violeta. **Hospital Universitario Río Hortega:** Abadía Otero Jéscia. **Hospital de Guadalajara:** Salillas Hernando Juan, Torres Sánchez del Arco Robert, Torralba González de Suso Miguel, Serrano Martínez Alberto, Gilaberte Reyzábal Sergio, Pacheco Martínez-Atienza Marina, Liébana Gómez Mónica, Fernández Rodríguez Sara, Varela Plaza Álvaro, Calvo Sánchez Henar. **Hospital Universitario Infanta Sofía:** Martínez Martín Patricia, González-Ruano Patricia, Malmierca Corral Eduardo, Rábago Lorite Isabel, Pérez-Monte Mínguez Beatriz. **Hospital Comarcal de Blanes:** García Flores Ángeles, Comas Casanova Pere. **Hospital Universitari de Tarragona Joan XXIII:** Sirisi Escoda Merce, Peraire Forner Joaquim. **Hospital Universitario Basurto:** Ibarra Ugarte Sofía, Muñoz Sanchez Pepa, López Azkarreta Iñigo. **Hospital Universitario de Canarias:** Alemán Valls Remedios, Alonso Socas María del Mar. **Hospital Universitario de Gran Canaria Dr. Negrín:** Sanz Peláez Oscar, Robaina Bordon Jose Maria. **Hospital Son Espases:** Riera Jaume Melchor, Vilchez Helem Haydee, Albertí Francesc, Cañabate Ana Isabel. **Hospital Universitario de Móstoles:** Moreno Cuerda Víctor J., Álvarez Kaelis Silvia, Álvarez Zapatero Beatriz, García García Alejandro, Isaba Ares Elena, Morcate Fernández Covadonga, Pérez Rodríguez Andrea. **Complejo Hospitalario Universitario A Coruña:** Ramos Merino Lucía, Castelo Corral

Laura, Rodríguez Mahía María, González Bardanca Mónica, Sánchez Vidal Efrén, Míguez Rey Enrique. **Hospital Costa del Sol:** Correa Ruiz Ana, García de Lomas Guerrero José M^a. **Hospital Clínico Universitario Lozano Blesa:** Cano Alberto, Alda Alicia, Merino Izarbe. **Hospital Mutua de Terrassa:** Gómez García Lucía, Boix Palop Lucía, Dietl Gómez-Luengo Beatriz. **Hospital de la Plana:** Pedrola Gorrea Iris, Blasco Claramunt Amparo. **Hospital Virgen de la Concha-Complejo Asistencial de Zamora:** López Mestanza Cristina, Fraile Villarejo Esther. **Complejo Hospitalario Universitario Insular Materno-Infantil:** Carmona Tello Maria Nieves, Suárez Hormiga Laura. **Hospital de la Marina Baixa:** Algado Rabasa José Tomas, Garijo Saiz Ana María, Amador Prous Concepción. **Hospital Universitario y Politécnico La Fe:** Tasías Pitarch Mariona. **Hospital Universitario del Vinalopó:** Hernández Belmonte Adriana, Pérez Soto María Isabel. **Hospital Parc Taulí de Sabadell:** Navarro Vilasaró Marta, Calzado Isbert Sonia, Cervantes García Manuel, Gomila Grange Aina, Gasch Blasi Oriol, Machado Sicilia María Luisa, Van den Eynde Otero Eva, Falgueras López Luis, Navarro Sáez María del Carmen. **Hospital Clinic de Barcelona:** Martínez Esteban, Marcos M^a Ángeles, Mosquera Mar, Blanco José Luis, Laguno Montserrat, Rojas Jhon, González-Cordón Ana, Inciarte Alexy, Torres Berta, De la Mora Lorena, Soriano Alex. **Hospital Universitario de la Ribera:** Martínez Macias Olalla, Borrás Máñez María. **Fundación Jiménez Díaz:** Cabello Úbeda Alfonso, Carrasco Antón Nerea, Álvarez Jiménez Beatriz, Petkova Saiz Elizabet, Górgolas Hernández-Mora Miguel, Prieto Pérez Laura, Carrillo Acosta Irene, Heili Frades Sara, Villar Álvarez Felipe, Fernández Roblas Ricardo, Milicua José María. **Hospital Clínico Universitario de Valladolid:** Fernández Espinilla Virginia, Castrodeza Sanz José Javier, Dueñas Gutiérrez Carlos Jesús. **Hospital Clínico San Carlos:** González-Romo Fernando, Merino Amador Paloma, Rueda López Alba, Martínez Jordán Jorge, Medrano Pardo Sara, Díaz de la Torre Irene, Posada Franco Yolanda, Delgado-Iribarren Alberto. **Hospital Santa Creu i Sant Pau:** López-Contreras González Joaquín, Pascual Alonso Pablo, Pomar Solchaga Virginia, Rabella García Nuria, Benito Hernández Natividad, Domingo Pedrol Pere, Bonfill Cosp Xavier, Padrós Selma Rafael, Puig Campmany Mireia, Mancebo Cortés Jordi, Navarro Risueño Ferran. **Clínica Universitaria de Navarra-Campus Madrid:** Íñigo Pestaña Melania, Pérez García Alejandra. **Hospital Son Llatzer:** Sorní Moreno Patricia, Izko Gartzia Nora. **Hospital General de la Defensa Gómez Ulla:** Membrillo de Novales Francisco Javier, Simón Sacristán María, Zamora Cintas Maribel, Torres Tienza Soledad, Estébanez Muñoz Miriam, Ramírez-Olivencia Germán, Ochoa Ruiz Ana María, Vazquez Jacinto Pedro, Mata Forte Tatiana, Ibañez Botella María del Alba. **Hospital Universitario de Álava:** Sáez de Adana Arróniz Ester, Portu Zapirain Joseba, Gainzarain Arana Juan Carlos, Ortiz de Zárate Ibarra Zuriñe, Moran Rodríguez Miguel Ángel, Canut Blasco Andrés, Hernáez Crespo Silvia, Fernandez Manandu Hansanee, Martínez Muñoz Ana, Salillas Santos Myriam, Wong Seoane Jessica. **Hospital Santos Reyes:** Hernández Roscales Javier, Grajal Merino Raquel. **Hospital Dr. José Molina Orosa:** Iglesias Llorente Laura, Espejo Gil Ana. **Hospital Vall d'Hebrón:** Sánchez Montalvá Adrián, Espinosa Pereiro Juan, Almirante Benito, Miarons Marta, Sellarés Júlia, Larrosa María Villamarín Miguel, Fernández Nuria, Salvador Fernando, Bosch-Nicolau Pau. **Hospital Universitario Rey Juan Carlos:** Pérez-Jorge Peremarch Conchita, Resino Foz Elena, Espigares Correa Andrea, Álvarez de Espejo Montiel Teresa, Navas Clemente Iván, Quijano Contreras María Isabel, Nieto Fernández del Campo Luis Alberto, Jiménez Álvarez Guillermo. **Complejo Hospitalario Universitario Santa Lucía:** Guillamón Sánchez Mercedes, García García Josefina. **Hospital Santa Bárbara:** Muñoz Hornero Constanza. **Complejo Hospitalario Universitario de Ferrol:** Mariño Callejo Ana, Valcarce Pardeiro Nieves. **Hospital de l'Esperit Sant:** Smithson Amat Alex, Chico Chumillas Cristina. **Hospital Universitario los Arcos del Mar Menor:** Sánchez Serrano Adriana, Piñar Cabezas Diana. **Hospital HLA Universitario Moncloa:** Jiménez Martínez Isabel, Villasante de la Puente Aránzazu, García Delange Teresa, Martínez Cilleros Carmen, Ruiz Rodríguez María José, Estrada Fernández Guillermo, Lorén Vargas

María, Parra Arribas Nuria, González Casanova Belén, Yagü Agueda Raquel. **Hospital Virgen del Puerto:** Muñoz del Rey José Román, Jiménez Álvaro Montaña. **Hospital Marina Salud de Dénia:** Coy Coy Javier, Poquet Catala Inmaculada. **Hospital Universitario de Jerez:** Santos Peña Marta, Mora Delgado Juan. **Hospital Reina Sofía de Tudela:** Manso Gómez Tamara, Rubio Obanos Teresa. **Hospital Clínico Universitario de Santiago de Compostela:** Barbeito Castiñeiras Gema, Trastoy Pena Rocío. **Hospital Universitario del Henares:** Mao Martín Laura, Adalid Moll María, Díaz Luperena Javier, Ruiz Grinspan Martín Sebastián, Alonso Navarro Rodrigo, Ampuero Martinich Jose David, Galindo Martín María Aránzazu, Martínez Avilés Rocío, Rodríguez Leal Cristóbal Manuel. **Hospital Universitario Lucus Augusti:** Romay Lema Eva María, Suárez Gil Roi. **Hospital de Donostia:** Iribarren Loyarte Jose Antonio, Bustinduy Odriozola Maria Jesús, Ibarguren Pinilla Maialen, Álvarez Rodríguez Ignacio. **Hospital de Urduliz Alfredo Espinosa:** Arriola Martínez Paula, Lartategi Iraurgi Alazne. **Hospital de Mendaro:** Álvarez de Castro Maria, Martínez Mateu Cintia María. **Hospital Juan Ramón Jiménez:** Rodríguez Gómez Francisco, Asschert Agüero Isabel. **Hospital de Tortosa Virgen de la Cinta:** Chamarro Martí Elena, Franch Llasat Diego. **Hospital Riotinto:** Zakariya-Yousef Breval Ismail, Rico Rodríguez Marta. **Hospital Vega Baja:** García Romero Laura, Jiménez Guardiola Carlos. **Hospital Puerta de Hierro:** Fernández Cruz Ana, Calderón Parra Jorge, Ramos Martínez Antonio, Múñez Rubio Elena, Vázquez Comendador José Manuel, Diego Yagüe Itziar, Expósito Palomo Esther, Blanco-Alonso Silvia, Muñoz-Gómez Ana, Delgado Téllez de Cepeda Laura. **Hospital Universitario de Getafe:** Álvarez Franco Raquel, Martínez Cifre Blanca, Aranda Rife Elena María, Roger Zapata Daniel, Cardona Arias Andrés Felipe, Fernández de Orueta Lucía, Vates Gómez Roberto, Marguenda Contreras Pablo, Martín Rubio Irene, Monereo Alonso Alfonso. **Hospital General de la Palma:** Barbosa Ventura André, Piñero Iván. **Hospital El Bierzo:** Bahamonde Carrasco Alberto, Martínez Vidal Ana. **Fundación Hospital de Calahorra:** Talavera García Eva, Mendoza Roy Paula. **Hospital Alto Deba:** Urrutia Losada Ainhoa, Artech Eguizabal Lorea. **Hospital Universitario San Juan de Alicante:** Delgado Sánchez Elisabet, Esteve-Atiénzar Pedro Jesús. **Hospital de Guadarrama:** Caro Bragado Sarah, Domínguez de Pablos Gema. **Hospital Universitario de Jaén:** Herrero Rodríguez Carmen, Liébana Martos Carmen. **Hospital de Mataró:** Force Sanmartín Luis, Arbones Laia. **Hospital de Palamós:** Mera Fidalgo Arantzazu, Marchena Romero José Andres. **Hospital Universitario de Valme:** Merchante Gutiérrez Nicolas, Espíndola Gómez Reinaldo. **Clínica Universitaria de Navarra-Campus Navarra:** Del Pozo León José Luís. **Hospital Clínica Benidorm:** Serralta Buades Josefa, Cabrera Tejada Ginger Giorgia. **Hospital Doce de Octubre:** Fernández-Ruiz Mario, Aguado José María, López-Medrano Francisco. **Hospital Universitario Ramón y Cajal:** Vizcarra Pilar, Rodríguez Domínguez Mario José, Gioia Francesca, Del Campo Santos, Cantón Moreno Rafael, Martín Dávila Pilar, Queda Carmen. **Hospital Universitario San Pedro:** Oteo Revuelta José Antonio, Santibáñez Sáenz Paula, Cervera Acedo Cristina, Pellejero Galadriel, Blanco Ramos José R., Azcona Gutiérrez José M., García García Concepción, Alba Fernández Jorge, Ibarra Cucalón Valvanera, Omato Sonia, Metola Sacristán Luis. **Hospital Quirón A Coruña:** Meijide Míguez Héctor, Paulos Viñas Silvia. **HM Sanchinarro:** Menéndez Justo, Villares Fernández Paula, Montes Andújar Lara. **Hospital Francesc de Borja:** Navarro Batet Álvaro, Ferrer Santolaria Anna. **Complejo Hospitalario Universitario Nuestra Señora de La Candelaria:** Padilla Salazar María de la Luz, Abella Vázquez Lucy, Hayek Peraza Marcelino, García Pardo Antonio, Hernández Carballo Carolina. **Hospital Universitario HM Montepíncipe:** Ruiz Fernández Andrés Javier, Barrio López Isabel. **Hospital Universitario HM Puerta del Sur:** Martakoush Ali. **Hospital Universitario HM Torrelodones:** Rojas-Vieyra Agustín. **Hospital Universitario HM Madrid:** García Calvo Sonia, Villarreal García-Lomas Mercedes. **Hospital Don Benito-Villanueva de la Serena:** Vizcaino Callejón Marta, García García María Pilar. **Hospital de Viladecans:** Llérida Urteaga Ana, Carrasco Fons Natalia, María Sanjuan Beatriz, Martín González Lydia, Sanz

Zamudio Camilo. **Centro Nacional de Epidemiología:** Alejos Belén, Moreno Cristina, Rava Marta, Iniesta Carlos, Izquierdo Rebeca, Suárez-García Inés, Díaz Asunción, Ruiz-Alguero Marta, Hernando Victoria.

CRediT authorship contribution statement

Sonsoles Salto-Alejandre: Conceptualization, Methodology, Software, Validation, Formal analysis, Writing – original draft, Visualization. **Zaira R Palacios-Baena:** Conceptualization, Methodology, Formal analysis, Supervision. **José Ramón Arribas:** **Juan Berenguer:** Investigation, Resources, Data curation. **Jordi Carratalà:** Investigation, Resources, Data curation. **Inmaculada Jarrín:** Investigation, Resources, Data curation. **Pablo Ryan:** Investigation, Resources, Data curation. **Marta de Miguel-Montero:** Investigation, Resources, Data curation. **Jesús Rodríguez-Baño:** Conceptualization, Methodology, Writing – review & editing, Supervision, Project administration, Funding acquisition. **Jerónimo Pachón:** Conceptualization, Methodology, Writing – review & editing, Supervision, Project administration, Funding acquisition.

Financial support

This work was primarily supported by Fundación SEIMC/GeSIDA (grant number COVID-19/SEIMC-FSG). The funders had no role in study design, data collection, data analysis, data interpretation or writing of the manuscript. Additionally, IJ, JB, JRA, JRB, JC, and JP received funding for research from Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, cofinanced by the European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020, through the following networks: Spanish AIDS Research Network (RIS) to IJ [grant number RD16CIII/0002/0006], JB [grant number RD16/0025/0017], and JRA [grant number RD16/0025/0018] and Spanish Network for Research in Infectious Diseases (REIPI) to JRB [grant number RD16/0016/0001], JC [grant number RD16/0016/0005], and JP [grant number RD16/0016/0009]. IJ [grant number CB21/13/00091], JB [grant number CB21/13/00044], JRA [grant number CB21/13/00039], JRB [grant number CB21/13/00012], and JC [grant number CB21/13/00009] also received support from the CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, cofinanced by the European Development Regional Fund.

Conflict of interest statement

JRA declares the following advisory fees and speaker fees: GSK, MSD, Serono, Lilly, Roche. The rest of the authors declare that there are no conflicts of interest.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.biopha.2021.112572.

References

- [1] Johns Hopkins University of Medicine: Coronavirus resource center. [Internet]. 2021. Available from: (<https://coronavirus.jhu.edu/map.html>).
- [2] Z. Abdelrahman, M. Li, X. Wang, Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses, Front Immunol. 11 (2020), 552909. (<https://pubmed.ncbi.nlm.nih.gov/33013925>).
- [3] Z. Wu, J.M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention, JAMA 323 (13) (2020) 1239–1242, <https://doi.org/10.1001/jama.2020.2648>.
- [4] A. Gupta, M.V. Madhavan, K. Sehgal, N. Nair, S. Mahajan, T.S. Sehrawat, et al., Extrapulmonary manifestations of COVID-19, Nat. Med. 26 (7) (2020) 1017–1032.

- [5] L.-Y.R. Wong, S. Perlman, Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? *Nat. Rev. Immunol.* (2021) 1–10.
- [6] Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* [Internet]. 2020/09/24. 2020 Oct 23;370(6515):eabd4570. Available from: (<https://pubmed.ncbi.nlm.nih.gov/32972995>).
- [7] Bastard P., Rosen LB, Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* [Internet]. 2020/09/24. 2020 Oct 23;370(6515):eabd4585. Available from: (<https://pubmed.ncbi.nlm.nih.gov/32972996>).
- [8] J.R. Teijaro, Type I interferons in viral control and immune regulation, *Curr. Opin. Virol.* 16 (2016) 31–40.
- [9] Major J., Crotta S., Llorian M., McCabe TM, Gad HH, Priestnall SL, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. *Science* [Internet]. 2020/06/11. 2020 Aug 7;369(6504):712–717. Available from: (<https://pubmed.ncbi.nlm.nih.gov/32527928>).
- [10] Hung IF-N., Lung K.-C., Tso EY-K., Liu R., Chung TW-H., Chu M.-Y., et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* (London, England) [Internet]. 2020/05/10. 2020 May 30;395(10238):1695–1704. Available from: (<https://pubmed.ncbi.nlm.nih.gov/32401715>).
- [11] I. Alavi Darazam, S. Shokouhi, M.A. Pourhoseingholi, S.S. Naghibi Irvani, M. Mokhtari, M. Shabani, et al., Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial, *Sci. Rep.* 11 (1) (2021) 8059 (Available from:), (<https://pubmed.ncbi.nlm.nih.gov/33850184>).
- [12] E. Davoudi-Monfared, H. Rahmani, H. Khalili, M. Hajjibaboli, M. Salehi, L. Abbasian, et al., A randomized clinical trial of the efficacy and safety of interferon β -1a in treatment of severe COVID-19, *Antimicrob. Agents Chemother.* 64 (9) (2020).
- [13] H. Pan, R. Peto, A.-M. Henao-Restrepo, M.-P. Preziosi, V. Sathiyamoorthy, Q. Abdool Karim, et al., Repurposed Antiviral Drugs for Covid-19 - interim WHO solidarity trial results, *New. Engl. J. Med.* 384 (6) (2021) 497–511.
- [14] A.C. Kalil, A.K. Mehta, T.F. Patterson, N. Erdmann, C.A. Gomez, M.K. Jain, et al., Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial, *Lancet Respir. Med.* 9 (12) (2021) 1365–1376.
- [15] Berenguer J., Ryan P., Rodríguez-Baño J., Jarrín I., Carratalá J., Pachón J., et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. *Clin Microbiol Infect* [Internet]. 2020/08/04. 2020 Nov;26(11):1525–1536. Available from: (<https://pubmed.ncbi.nlm.nih.gov/32758659>).
- [16] Rodríguez-Baño J., Pachón J., Carratalá J., Ryan P., Jarrín I., Yllescas M., et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). *Clin Microbiol Infect* [Internet]. 2020/08/27. 2021 Feb;27(2):244–252. Available from: (<https://pubmed.ncbi.nlm.nih.gov/32860964>).
- [17] Gutiérrez-Gutiérrez B., Del Toro MD, Borobia AM, Carcas A., Jarrín I., Yllescas M., et al. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis* [Internet]. 2021/02/23. 2021 Jun;21(6):783–792. Available from: (<https://pubmed.ncbi.nlm.nih.gov/33636145>).
- [18] Berenguer J., Borobia AM, Ryan P., Rodríguez-Baño J., Bellón JM, Jarrín I., et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax* [Internet]. 2021 Feb 25;thoraxjnl-2020-216001. Available from: (<https://pubmed.ncbi.nlm.nih.gov/33632764>).
- [19] P.A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, J.G. Conde, Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, *J. Biomed. Inf.* 42 (2) (2009) 377–381.
- [20] E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Göttsche, J. P. Vandenbroucke, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, *J. Clin. Epidemiol.* 61 (4) (2008) 344–349.
- [21] infection WHOWG on the CC and M of C-19. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* [Internet]. 2020/06/12. 2020 Aug;20(8):e192–e197. Available from: (<https://pubmed.ncbi.nlm.nih.gov/32539990>).
- [22] E. Bosi, C. Bosi, P. Rovere Querini, N. Mancini, G. Calori, A. Ruggeri, et al., Interferon β -1a (IFN β -1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial, *Trials* 21 (1) (2020) 939, <https://doi.org/10.1186/s13063-020-04864-4>.
- [23] N. Clementi, R. Ferrarese, E. Criscuolo, R.A. Diotti, M. Castelli, C. Scagnolari, et al., Interferon- β -1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection, *J. Infect. Dis.* 222 (5) (2020) 722–725.
- [24] T.P. Sheahan, A.C. Sims, S.R. Leist, A. Schäfer, J. Won, A.J. Brown, et al., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, *Nat. Commun.* 11 (1) (2020) 222. (<https://pubmed.ncbi.nlm.nih.gov/31924756>).
- [25] Chan JF-W., Yao Y., Yeung M.-L., Deng W., Bao L., Jia L., et al. Treatment With Lopinavir/Ritonavir or Interferon- β 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. *J Infect Dis* [Internet]. 2015/07/21. 2015 Dec 15;212(12):1904–1913. Available from: (<https://pubmed.ncbi.nlm.nih.gov/26198719>).
- [26] Y.M. Arabi, A.Y. Asiri, A.M. Assiri, H.H. Balkhy, A. Al Bshabshe, M. Al Jeraisy, et al., Interferon beta-1b and lopinavir-ritonavir for middle east respiratory syndrome, *New Engl. J. Med.* 383 (17) (2020) 1645–1656.
- [27] V.M. Ranieri, V. Pettilä, M.K. Karvonen, J. Jalkanen, P. Nightingale, D. Brealey, et al., Effect of intravenous interferon β -1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial, *JAMA* 323 (8) (2020) 725–733.
- [28] PRISMS-4, Long-term efficacy of interferon-beta-1a in relapsing MS, *Neurology* 56 (12) (2001) 1628–1636.
- [29] P.D. Monk, R.J. Marsden, V.J. Tear, J. Brookes, T.N. Batten, M. Mankowski, et al., Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial, *Lancet Respir. Med.* 9 (2) (2021) 196–206.
- [30] S. Salto-Alejandre, C. Roca-Oporto, G. Martín-Gutiérrez, M.D. Avilés, C. Gómez-González, M.D. Navarro-Amuedo, et al., A quick prediction tool for unfavourable outcome in COVID-19 inpatients: development and internal validation, *J. Infect.* 82 (2) (2020) e11–e15.
- [31] S. Salto-Alejandre, S. Jiménez-Jorge, N. Sabé, A. Ramos-Martínez, L. Linares, M. Valerio, et al., Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: a prospective multicenter cohort study, *PLoS One* 16 (4) (2021) e0250796.
- [32] A.T. Reder, D. Centonze, M.L. Naylor, A. Nagpal, R. Rajbhandari, A. Altincatal, et al., COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies, *CNS Drugs* 35 (3) (2021) 317–330.
- [33] F. Diaz-San Segundo, G.N. Medina, P. Azzinaro, J. Gutkoska, A. Mogulothu, S. E. Atreud, et al., Use of protein pegylation to prolong the antiviral effect of IFN against FMDV, *Front. Microbiol.* 12 (2021) 668890.
- [34] Y. Ma, J. Wang, F. Xiong, J. Lu, Extended duration therapy regimens based on Pegylated Interferon for Chronic Hepatitis B patients focusing on hepatitis B surface antigen loss: a systematic review and meta-analysis, *Infect., Genet. Evol.* 85 (2020) 104492.